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luting Coronary Stent System in the Treatment of Patients With De Novo Native
oronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational
evice XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of
ubjects With De Novo Native Coronary Artery Lesions) Randomized Trials
driano Caixeta, MD, PHD,* Alexandra J. Lansky, MD,* Patrick W. Serruys, MD, PHD,†
ames B. Hermiller, MD,‡ Peter Ruygrok, MD,§ Yoshinobu Onuma, MD,†
aul Gordon, MD, Manejeh Yaqub, MD,¶ Karine Miquel-Hebert, PHD,#
usan Veldhof, RN,# Poornima Sood, MD, MBA,¶ Xiaolu Su, MS,¶
alitha Jonnavithula, MBA,¶ Krishnankutty Sudhir, MD, PHD,¶ Gregg W. Stone, MD,*
or the SPIRIT II and III Investigators
ew York, New York; Rotterdam, the Netherlands; Indianapolis, Indiana; Auckland, New Zealand;
rovidence, Rhode Island; Santa Clara, California; and Diegem, Belgium
bjectives The purpose of this study was to investigate long-term 3-year clinical outcomes of an
verolimus-eluting stent (EES) versus a paclitaxel-eluting stent (PES).
ackground Compared with PES, EES reduced target vessel failure and major adverse cardiac
vents at 2 years. Whether the beneﬁts of EES are sustained at 3 years has not been reported.
ethods In the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent
ystem in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A
linical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent Sys-
em [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) trials,
,302 patients were randomly assigned to EES (n  892) or PES (n  410). We report the 3-year
linical follow-up of this patient-level pooled analysis.
esults At 3 years, EES compared with PES resulted in a signiﬁcant reduction in myocardial infarction
3.8% vs. 6.7%; relative risk [RR]: 0.56; 95% conﬁdence interval [CI]: 0.34 to 0.94; p  0.04), and target
esion revascularization (6.8% vs. 12.7%; RR: 0.53; 95% CI: 0.37 to 0.77; p  0.001). Everolimus-eluting
tents resulted in a signiﬁcant reduction in target vessel failure (13.7% vs. 19.5%; RR: 0.70; 95% CI: 0.54 to
.92; p  0.01), and major adverse cardiac events (9.1% vs. 16.3%; RR: 0.56; 95% CI: 0.41 to 0.76; p 
.0004). The cumulative rates of Academic Research Consortium–deﬁned deﬁnite or probable stent
hrombosis were 1.2% in EES patients and 1.9% in PES patients (RR: 0.64; 95% CI: 0.25 to 1.68; p  0.43).
onclusions In this patient-level pooled analysis, EES compared with PES resulted in a signiﬁcant and
ersistent reduction in target vessel failure and major adverse cardiac events at 3 years due to fewer
yocardial infarction and ischemic target lesion revascularization events, which is consistent with supe-
ior safety and efﬁcacy of the EES platform. (A Clinical Evaluation of the XIENCE V Everolimus Eluting Cor-
nary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions [SPIRIT II];
CT00180310) (SPIRIT III: A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting
oronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Le-
ions [SPIRIT III]; NCT00180479) (J Am Coll Cardiol Intv 2010;3:1220–8) © 2010 by the American College
f Cardiology Foundation
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1221irst-generation stainless steel drug-eluting stents (DES),
ncluding sirolimus-eluting stents (SES) and paclitaxel-
luting stents (PES), have significantly reduced rates of
estenosis and target lesion revascularization (TLR) com-
ared with bare-metal stents (1–3). However, delayed re-
ndothelialization and suppression of vascular healing with
oth SES and PES have been associated with increased
ates of late and very late stent thrombosis (4–7), as well as
yocardial infarction (MI) and death (8). Furthermore,
n-stent restenosis after DES can still occur, especially in
atients with complex coronary artery disease (9). Addi-
ional limitations of first-generation DES include enhanced
latelet aggregation and inflammation, polymer hypersen-
itivity reactions, high rates of late-acquired incomplete
tent apposition, and strut fractures (10–14). Improved
tent designs with thinner struts and more biocompatible
olymer coatings and optimized drug elution profiles might
avorably influence DES performance.
The clinical safety and efficacy of the everolimus-eluting
tent (EES) is currently being tested in the SPIRIT family
f randomized controlled trials. In both the SPIRIT II (A
linical Evaluation of the XIENCE V Everolimus Eluting
oronary Stent System in the Treatment of Patients With
e Novo Native Coronary Artery Lesions) (15) and
PIRIT III (A Clinical Evaluation of the Investigational
evice XIENCE V Everolimus Eluting Coronary Stent
ystem [EECSS] in the Treatment of Subjects With De
ovo Native Coronary Artery Lesions) (16) trials, the
ience V EES was superior to the Taxus PES for primary
ngiographic end points in reducing in-stent late loss at 6
onths and in-segment late loss at 8 months, respectively.
n the SPIRIT III trial, EES also demonstrated superiority
o PES for the coprimary clinical end point of target vessel
ailure (TVF) and major adverse cardiac events (MACE) at
years. The 2-year outcomes of the pooled SPIRIT II and
PIRIT III trials demonstrated the benefit of the EES at 2
ears (17). Whether the benefits of EES are sustained or
ncrease with longer-term follow-up remains unknown. We,
herefore, examined the 3-year outcomes in a pooled anal-
sis of the SPIRIT II and III trials.
ethods
atient population and study design. This study represents
patient-level pooled analysis of the SPIRIT II and
PIRIT III prospective, multicenter, single-blind, con-
rom the *Columbia University Medical Center and the Cardiovascular Research
oundation, New York, New York; †Thoraxcenter, Erasmus Medical Center,
otterdam, the Netherlands; ‡Heart Center of Indiana, Indianapolis, Indiana;
Green Lane, Cardiovascular Service, Auckland, New Zealand; Miriam Hospital,
rovidence, Rhode Island; ¶Abbott Vascular, Santa Clara, California; and #Abbott
ascular, Diegem, Belgium. Sponsored by Abbott Vascular. Dr. Lansky has receivedesearch grants from The Medicines Co., Cordis, Boston Scientific, Medtronic, and
bbott. Dr. Hermiller is a research consultant for Abbott Vascular. Dr. Gordon has
M
arolled randomized clinical trials, in which patients with de
ovo lesions were treated with either polymer-based EES
Xience V, Abbott Vascular, Santa Clara, California) or
ith polymer-based PES (Taxus Express2, Boston Scien-
ific, Natick, Massachusetts). The protocol and principal
esults of each trial have been published previously (15,16).
n brief, in the SPIRIT II trial, 300 patients in Europe,
ndia, and New Zealand were randomized in a 3:1 ratio to
eceive EES (Xience V, n  223) or PES (n  77 [Taxus
xpress2, n  59 or Taxus Liberté, n  17, with 1 patient
eceiving a nonstudy stent]) (15). In SPIRIT III, 1,002
atients were randomized at 65 U.S. sites in a 2:1 ratio to
eceive the Xience V EES (n  669) or the Taxus Express2
ES (n  333). The studies were approved by the institu-
ional review board or ethics committee at each participating
enter, and all patients provided written informed consent.
edication and follow-up. The
rial protocols recommended in-
efinite use of aspirin 75 mg
aily and clopidogrel 75 mg daily
or a minimum of 6 months. In
PIRIT II, protocol-specified an-
iographic follow-up was planned
n all patients at 6 months and in
subgroup of 152 patients at 2
ears. In SPIRIT III, angio-
raphic follow-up was planned in
subset of 564 patients at 8
onths. Clinical follow-up was
erformed at 1, 6, and 9 months,
nd 1 year and then annually
hrough 5 years in both studies.
hree-year clinical follow-up was
vailable in 1,224 patients (94%),
ncluding 839 EES patients and
85 PES patients.
eﬁnitions and clinical end
oints. The safety end points for
his analysis included rates of cardiac death, MI, stent throm-
osis defined as definite and probable by Academic Research
onsortium (ARC) (18), as well as the composite of cardiac
eath or MI. Efficacy end points included target vessel revas-
ularization (TVR) and TLR. Combined safety and efficacy
nd points included TVF, defined as the composite of cardiac
eath, MI, or ischemia-driven TVR by either percutaneous
oronary intervention or bypass graft surgery, and MACE, de-
eceived research support from Abbott Vascular. Dr. Yaqub, Dr. Miquel-Hebert,
usan Veldhof, Dr. Sood, Xiaolu Su, Lalitha Jonnavithula, and Dr. Sudhir are
mployed by and hold equity in Abbott Vascular. Dr. Stone serves on the scientific
dvisory boards for and has received honoraria from Abbott Vascular and Boston
cientific. All other authors have reported that they have no relationships to disclose.
Abbreviations
and Acronyms
ARC  Academic Research
Consortium
DES  drug-eluting stent(s)
EES  everolimus-eluting
stent(s)
MACE  major adverse
cardiac events
MI  myocardial infarction
PES  paclitaxel-eluting
stent(s)
SES  sirolimus-eluting
stent(s)
TLR  target lesion
revascularization
TVF  target vessel failure
TVR  target vessel
revascularizationanuscript received May 18, 2010; revised ma
ccepted July 25, 2010.nuscript received July 14, 2010,
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1222ned as the composite of cardiac death, MI, or ischemia-driven
LR.
ata management and statistical analysis. Study monitors
erified all case report form data on site. All MACE events
ere adjudicated by independent clinical event committees
linded to treatment assignment with review of original
ource documentation. Retrospectively, all stent thrombosis
vents were readjudicated using the ARC definitions (18).
Given the similarity in the inclusion and exclusion criteria
nd test arms in the 2 trials, the patient-level databases from
he 2 trials were pooled comparing EES and PES. Continuous
ariables are expressed as mean  SD and compared by t test.
inary variables are presented as counts and percentages and
ere compared using the Fisher exact test. All p values are
-tailed and not from formal hypothesis testing and are shown
or descriptive purposes only. All analyses are by intention-to-
reat using all patients randomized in the study, regardless of
Table 1. Baseline Characteristics and Antiplatelet M
EES
Clinical features
Age, yrs 62.91
Male 70.3% (627
Diabetes mellitus 27.9% (249
Insulin-requiring 7.1% (63 o
Hypertension 74.0% (660
Hypercholesterolemia 72.8% (638
Current smoking 25.3% (220
Prior MI 23.7% (207
Stable angina 55.5% (488
Unstable angina 20.8% (183
Lesions treated 1,03
Target vessels
Left anterior descending 41.1% (423
Left circumﬂex 28.0% (288
Right 30.7% (316
Left main (protected) 0.1% (1 of
Target lesion
Reference vessel diameter, mm 2.73 (2.42
Lesion length, mm 12.9 (10.0
Aspirin use*
At 6 months 97.6% (842
At 1 yr 97.0% (818
At 2 yrs 95.8% (771
At 3 yrs 93.7% (739
Thienopyridine use*
At 6 months 94.1% (823
At 1 yr 63.7% (544
At 2 yrs 50.2% (409
At 3 yrs 46.1% (369
Values aremean SD,% (n), n, ormedian (interquartile range). *With
clopidogrel or ticlopidine. This category excludes early terminated subj
window.EES everolimus-eluting stent(s); IQR interquartile range; MImyocardhe treatment actually received. Patients lost to follow-up in
hom no event had occurred before the follow-up windows
ere not included in the denominator for calculations of binary
nd points. Relative risk was calculated as the event rate of the
ES arm divided by the event rate of the PES arm. Three-year
utcomes are summarized as Kaplan-Meier estimates and
ompared using log-rank test and hazard ratios. Time-to-event
azard curves also are presented and compared by log-rank
est. To assess events occurring between 1 and 3 years, a
andmark analysis was performed. Cox proportional hazard
odels were used to calculate the hazard ratios of the EES
ersus PES groups. To explore the interaction between
ubgroups and the treatment effect for TVF and MACE,
post hoc logistic regression analysis was performed and
values were calculated by Wald chi-square statistics. All
tatistical tests were 2-tailed and a p value 0.05 denoted
ignificance. All statistical analyses were performed by
tion Use
PES p Value
62.63 10.09 0.65
) 68.2% (279 of 409) 0.48
) 27.1% (110 of 406) 0.79
5.7% (23 of 406) 0.40
) 72.3% (295 of 408) 0.54
) 72.4% (291 of 402) 0.89
) 23.8% (93 of 391) 0.57
) 19.3% (78 of 404) 0.08
) 50.5% (204 of 404) 0.10
) 26.5% (107 of 404) 0.03
474
8) 43.8% (207 of 473) 0.37
8) 26.4% (125 of 473) 0.53
8) 29.6% (140 of 473) 0.67
0.2% (1 of 473) 0.53
2.77 (2.43–3.04) 0.41
13.0 (10.5–17.2) 0.63
) 97.2% (380 of 391) 0.70
) 96.9% (369 of 381) 0.86
) 95.1% (346 of 364) 0.65
) 94.4% (335 of 355) 0.69
) 93.7% (372 of 397) 0.80
) 64.6% (250 of 387) 0.80
) 55.4% (205 of 370) 0.10
) 50.3% (181 of 360) 0.20
windows. Thienopyridine use includes patientswho are taking either
hout anyvalid records for using relatedprotocolmedication inside theedica
10.48
of 892
of 892
f 892)
of 892
of 876
of 869
of 873
of 880
of 880
2
of 1,02
of 1,02
of 1,02
1,028)
–3.05)
–17.7)
of 863
of 843
of 805
of 789
of 875
of 854
of 815
of 800
1-week
ectswitial infarction; PES paclitaxel-eluting stent(s).
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1223AS software (version 9.1.3, SAS Institute, Cary, North
arolina).
esults
aseline and procedural characteristics. In the SPIRIT II
nd III trials, 1,302 patients at 93 international centers were
andomly assigned to receive either EES (n  892) or PES
n  410). The baseline clinical and angiographic characteris-
ics were well matched between the 2 groups, except for a
lightly lower incidence of unstable angina in patients random-
zed to EES (Table 1). The overall follow-up rate at 3 years for
PIRIT II and III patients was 94.1% in the EES arm and
Table 2. Cumulative Clinical Outcomes Up to 3 Years
EES
0–3 yrs
All-cause death 3.2% (27 of 839) 5
Cardiac death 1.3% (11 of 839) 2
Noncardiac death 1.9% (16 of 839) 3
MI 3.8% (31 of 824) 6
Q-wave 0.4% (3 of 824) 0
Non–Q-wave 3.4% (28 of 824) 6
All-cause death or MI 6.6% (55 of 839) 11
Cardiac death or MI 4.9% (40 of 824) 8
TLR, all 6.8% (57 of 839) 12
Ischemia-driven 5.4% (45 of 839) 9
Nonischemia-driven 1.7% (14 of 839) 5
TVR, all 12.2% (102 of 839) 16
Ischemia-driven 10.5% (88 of 839) 14
Nonischemia-driven 2.9% (24 of 839) 6
MACE 9.1% (75 of 824) 16
TVF 13.7% (113 of 824) 19
1–3 yrs
All-cause death 1.9% (16 of 824) 3
Cardiac death 0.7% (6 of 824) 1
Noncardiac death 1.2% (10 of 824) 2
MI 1.4% (11 of 814) 2
Q-wave 0.1% (1 of 814) 0
Non–Q-wave 1.2% (10 of 814) 2
All-cause death or MI 3.2% (26 of 824) 5
Cardiac death or MI 2.0% (16 of 814) 3
TLR, all 2.8% (23 of 824) 4
Ischemia-driven 2.5% (21 of 824) 3
Nonischemia-driven 0.2% (2 of 824) 0
TVR all 5.6% (46 of 824) 6
Ischemia-driven 5.1% (42 of 824) 6
Nonischemia-driven 0.6% (5 of 824) 0
MACE 3.9% (32 of 814) 6
TVF 6.3% (51 of 814) 9
Values are % (n).
CI  confidence interval; MACE  cardiac death, MI, or ischemia-d
cardiac death, MI, or ischemia-driven TVR; TVR target vessel revascu3.9% in the PES arm. Aspirin use was high in both groups chroughout the 3-year follow-up, whereas thienopyridine use
eclined progressively over time. Compliance with dual anti-
latelet therapy was also similar between the EES and PES
roups at 3-year follow-up (43.4% vs. 47.0%; p  0.27).
linical outcomes at 3 years. Table 2 displays the major
linical end points at 3 years, and between 1 and 3 years. At
-year follow-up, treatment with EES resulted in a 30%
ecrease in the rate of TVF (13.7% vs. 19.5%; p 0.01) and
44% decrease in MACE (9.1% vs. 16.3%; p  0.0004).
he reduction in TVF and MACE with EES at 3 years was
riven by both a 45% relative reduction in non–Q-wave MI
nd a 41% relative reduction in ischemia-driven TLR
Table 2). In addition, there is a 41% decrease in the
Between 1 and 3 Years
ES Relative Risk [95% CI] p Value
1 of 385) 0.59 [0.34–1.03] 0.08
of 385) 0.56 [0.23–1.34] 0.22
2 of 385) 0.61 [0.29–1.28] 0.22
5 of 374) 0.56 [0.34–0.94] 0.04
of 374) 0.68 [0.11–4.06] 0.65
3 of 374) 0.55 [0.32–0.95] 0.04
3 of 385) 0.59 [0.40–0.86] 0.009
1 of 374) 0.59 [0.37–0.92] 0.02
9 of 385) 0.53 [0.37–0.77] 0.001
5 of 385) 0.59 [0.39–0.90] 0.02
1 of 385) 0.31 [0.16–0.60] 0.0006
5 of 385) 0.72 [0.54–0.96] 0.03
4 of 385) 0.75 [0.54–1.03] 0.08
3 of 385) 0.48 [0.27–0.84] 0.01
1 of 374) 0.56 [0.41–0.76] 0.0004
3 of 374) 0.70 [0.54–0.92] 0.01
4 of 377) 0.52 [0.26–1.06] 0.07
of 377) 0.55 [0.17–1.79] 0.34
of 377) 0.51 [0.21–1.24] 0.14
of 368) 0.55 [0.23–1.32] 0.22
of 368) 0.45 [0.03–7.21] 0.53
of 368) 0.57 [0.22–1.42] 0.30
2 of 377) 0.54 [0.31–0.94] 0.04
3 of 368) 0.56 [0.27–1.14] 0.15
5 of 377) 0.70 [0.37–1.33] 0.29
4 of 377) 0.69 [0.35–1.33] 0.27
of 377) 0.46 [0.06–3.24] 0.59
6 of 377) 0.81 [0.51–1.29] 0.36
6 of 377) 0.74 [0.46–1.19] 0.23
of 377) 1.14 [0.22–5.87] 1.00
5 of 368) 0.58 [0.35–0.96] 0.04
6 of 368) 0.64 [0.43–0.96] 0.04
R; TLR  target lesion revascularization; TVF  target vessel failure:
n; other abbreviations as in Table 1.and
P
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1224hown in Figure 1, the absolute benefits of EES compared
ith PES achieved by 1 year continued to spread through
he 3-year follow-up. Between 1 and 3 years of follow-up,
ES resulted in a 36% decrease in the rate of TVF (6.3% vs.
.8%, p  0.04) and in a 42% decrease in MACE (3.9% vs.
.8%, p  0.04) (Fig. 2) (Table 2).
The rates of ARC-defined definite and probable stent
hrombosis were not significantly different between the 2
Figure 1. Time-to-Event Curves for Patients Treated With EES or PES
Three-year cumulative event curves for (A) target vessel failure; (B) major adve
revascularization; and (E) Academic Research Consortium–deﬁned deﬁnite or p
up to 3-year follow-up. ARC  Academic Research Consortium; EES  everolim
 myocardial infarction; PES  paclitaxel-eluting stent(s); ST  stent thrombotent types (1.2% with EES and 1.9% with PES; p  0.43) ETable 3). The rate of very late (1 year) definite or
robable stent thrombosis was numerically lower but not
ignificantly different in the EES group (0.5% of EES and
.1% of PES; p  0.26) (Table 3).
ubgroup analysis. Logistic regression analysis was per-
ormed to assess whether the reduction in TVF and MACE
n EES-treated compared with PES-treated patients was
onsistent among different subgroups. Treatment benefit of
rdiac event; (C) cardiac death or myocardial infarction; (D) target lesion
le stent thrombosis. Note that each curve depicts the hazard ratio annually
ting stent(s); HR  hazard ratio; MACE  major adverse cardiac events; MI
R  target lesion revascularization; TVF  target vessel failure.rse ca
robab
us-eluES was seen in all subgroups tested for TVF (Fig. 3) and
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1225or MACE (Fig. 4), except for patients with diabetes.
mong the 326 patients with diabetes, the 3-year rate of
ACE was 12.0% in the EES group compared with 10.8%
n the PES group (relative risk [RR]: 1.12, 95% confidence
nterval [CI]: 0.57 to 2.21), whereas, in those without
iabetes, the rate was 8.0% in the EES group compared
ith 18.3% in the PES group (RR: 0.43, 95% CI: 0.30 to
.63). The relative reduction in MACE with EES com-
ared with PES was comparable in both patients undergo-
ng and not undergoing angiographic follow-up.
iscussion
his patient-level pooled analysis demonstrates the signif-
cant and sustained reduction in TVF and MACE among
Figure 2. 1-Year Landmark Analysis of Ischemic MACE and TVF
Time-to-event curves with landmark analysis from 0 to 1 and 1 to 3 years for (A)
Table 3. Incidence of Stent Thrombosis According to
EES
All (0 – 3 yrs)
Deﬁnite ST 0.9% (7 of 811)
Probable ST 0.4% (3 of 811)
Deﬁnite or probable ST 1.2% (10 of 811)
Early (0–30 days)
Deﬁnite ST 0.3% (3 of 890)
Probable ST 0.0% (0 of 890)
Deﬁnite or probable ST 0.3% (3 of 890)
Late (31 days –1 yr)
Deﬁnite ST 0.2% (2 of 869)
Probable ST 0.1% (1 of 869)
Deﬁnite or probable ST 0.3% (3 of 869)
Very late (1–3 yrs)
Deﬁnite ST 0.2% (2 of 809)
Probable ST 0.2% (2 of 809)
Deﬁnite or probable ST 0.5% (4 of 809)
Values are % (n).ARC Academic Consortium Research; NA not applicable; ST stent thatients with de novo coronary artery lesions treated with
ES compared with PES to 3-year follow-up. Everolimus-
luting stents demonstrated improved efficacy and safety
ver time, with robust reductions in ischemia-driven TLR
nd TVR as well as significant and sustained reductions in
I and composite death or MI.
ong-term safety and efﬁcacy of EES. This report provides
nformation on the latest (3-year) follow-up of patients
reated with EES. After the completion of 1-year follow-up,
atients treated with EES compared with those treated with
ES had fewer episodes of MI, TLR, TVR, and death. The
ime-to-event curves for TVF and MACE between 1 and 3
ears have continued to diverge, resulting in a significant 30%
elative reduction in TVF and a 44% relative reduction in
d (B) MACE. Abbreviations as in Figure 1.
Definition
ES Relative Risk [95% CI] p Value
4 of 366) 0.79 [0.23–2.68] 0.75
4 of 366) 0.34 [0.08–1.50] 0.21
7 of 366) 0.64 [0.25–1.68] 0.43
1 of 407) 1.37 [0.14–13.15] 1.00
0 of 407) — NA
1 of 407) 1.37 [0.14–13.15] 1.00
1 of 393) 0.90 [0.08–9.95] 1.00
2 of 393) 0.23 [0.02–2.49] 0.23
3 of 393) 0.45 [0.09–2.23] 0.38
2 of 364) 0.45 [0.06–3.18] 0.59
2 of 364) 0.45 [0.06–3.18] 0.59
4 of 364) 0.45 [0.11–1.79] 0.26ARC
P
1.1% (
1.1% (
1.9% (
0.2% (
0.0% (
0.2% (
0.3% (
0.5% (
0.8% (
0.5% (
0.5% (
1.1% (rombosis; other abbreviations as in Tables 1 and 2.
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1226ACE at 3-year follow-up. The improved clinical outcomes
emonstrated at 1 year and 2 years (17) in patients receiving
ES compared with those receiving PES have become even
ore pronounced at 3-year follow-up.
The present analysis is consistent with the clinical results
rom 2 recent randomized studies demonstrating superior
afety and efficacy of EES compared with PES. In the
arge-scale SPIRIT IV (Clinical Evaluation of the Xience V
verolimus Eluting Coronary Stent System in the Treat-
ent of Patients With De Novo Native Coronary Artery
esions IV) trial (19), randomization of 3,687 patients—
ncluding a more complex patient subgroup with more than
,100 patients with diabetes—to EES (Xience V) or PES
Taxus Express2) resulted in a significant 38% relative
eduction in the 1-year end points of target lesion failure (a
omposite of cardiac death, target vessel MI, or ischemia-
riven TLR), cardiac death, MI, or ischemia-driven TLR at
-year follow-up. Likewise, in the COMPARE (Second-
eneration Everolimus-Eluting and Paclitaxel-Eluting
tents in Real-Life Practice) trial (20), a randomization of
,800 unselected patients to EES (Xience V) or PES (Taxus
iberté) also resulted in a significant 33% relative reduction
n the 1-year primary end point (all-cause mortality, nonfatal
Figure 3. TVF Rates Among Subgroups in SPIRIT II and III Trials
Subgroup analyses of the 3-year rates of TVF among patients randomized to E
reference vessel diameter; SPIRIT II  A Clinical Evaluation of the XIENCE V Eve
Native Coronary Artery Lesions; SPIRIT III  A Clinical Evaluation of the Investig
Treatment of Subjects With De Novo Native Coronary Artery Lesions; other abI, and TVR) and nonfatal MI. The current analysis confirms bnd extends the results from the SPIRIT IV and COMPARE
rials in demonstrating that EES continues to be both safer and
ore efficacious than PES through 3-year follow-up.
Use of first-generation SES and PES has been associated
ith increased rates of stent thrombosis compared with bare-
etal stents, particularly after 1 year of follow-up (4–7). In this
ooled analysis, the rates of stent thrombosis were comparable
etween EES and PES within the first year after implantation.
onetheless, there was a trend for fewer ARC-defined definite
r probable very late stent thrombosis episodes with EES
ompared with PES (0.5% vs. 1.1%, respectively). However,
he SPIRIT II and III trials were underpowered to evaluate
ifferences in stent thrombosis between these 2 devices.
onger-term follow-up from the larger SPIRIT IV (19) and
OMPARE (20) trials are required to determine whether very
ate stent thrombosis is less common with EES compared with
ES, especially in complex coronary lesions.
The reduced rate in the composite safety and efficacy end
oints of TVF and MACE with EES compared with PES
n the present analysis was attributable to fewer TLR and
eriprocedural non–Q-wave MI events. The lower rate of
LR (i.e., superior efficacy) with EES compared with PES
ay be directly attributed to reductions in late lumen loss,
the PES. LAD  left anterior descending artery; RR  relative risk; RVD 
us Eluting Coronary Stent System in the Treatment of Patients With De Novo
al Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the
tions as in Figure 1.ES or
rolim
ationinary restenosis, and neointimal hyperplasia in the target
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1227esion, as previously described (15,16). Importantly, the
arly reduction in TLR with EES is sustained through 3
ears, although longer-term (5 years) follow-up is required
o assess the late durability of these clinical advantages. In
ddition to efficacy, EES was safer than PES, with fewer
Is and composite death or MI, as also seen in the SPIRIT
V (19) and COMPARE (20) trials. In the SPIRIT II and
II trials, the increased rates of MI were due mostly to an
ncrease in periprocedural non–Q-wave MIs. The likely
ause is less side-branch compromise due to thinner poly-
er/stent interface of EES compared with PES (89 m vs.
48 m), which was also shown to be the possible cause of
ower rates of 30-day MI with the Express bare-metal stent
ompared with PES in the TAXUS V trial (9). Lansky et al.
21) have recently demonstrated less side branch occlusion
ith EES compared with PES in the SPIRIT III trial, a
nding correlated with lower non–Q-wave MIs in the EES
reatment group.
ubgroup analysis. The 3-year reduction in TVF with EES
ompared with PES was consistent across all subgroups
xcept patients with diabetes. A significant interaction was
oted between diabetic status and stent type with respect to
ACE, similar to findings reported in SPIRIT IV at 1 year
19). Conflicting findings from prior studies comparing
ES and PES in diabetic patients also have been reported;
Figure 4. MACE Rates Among Subgroups in SPIRIT II and III Trials
Subgroup analyses of the 3-year rates of MACE among patients randomized toome studies suggested that stents eluting everolimus or birolimus might offer advantages over PES (22,23), whereas
thers reported disadvantages (24,25). These drugs (e.g.,
irolimus and everolimus) may be less effective in inhibiting
eointimal formation in diabetic compared with nondia-
etic patients. In the SPIRIT IV trial, target lesion failure
ates were similar in diabetic patients receiving an EES or
ES at 1 year, though stent thrombosis rates were nonsig-
ificantly lower in the EES treatment group. Differences in
he mechanisms of action of the drugs may explain the
nconsistent outcomes with EES compared with PES in the
iabetic cohort (26). In the pooled analysis, the performance
f the EES in the diabetic subgroup was similar to nondia-
etics patients, whereas PES performance was significantly
etter than in nondiabetics patients. However, it should be
oted that post hoc subgroup analyses often are statistically
nderpowered, which can lead to overstated and misleading
esults (27).
tudy limitations. Several limitations of the present study
hould be acknowledged. First, the SPIRIT II and SPIRIT
II trials were originally designed and powered to evaluate a
eduction in angiographic in-stent and in-segment late loss
nd noninferiority for the clinical end point TVF for the
ntire study population as a whole. Thus, the results of the
resent patient-pooled analysis combining the 2 studies are
ypothesis-generating only. A few minor differences exist
r the PES. Abbreviations as in Figures 1 and 3.etween the 2 studies, including the percentage of patients
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1228ndergoing follow-up angiography and the timing of
ollow-up, as well as differing proportions of patients receiv-
ng PES. Second, although 2 larger, randomized trials with
ore complex and previously unstudied lesions demon-
trated a significant reduction in the primary clinical end
oint of target lesion failure and MACE in EES- compared
ith PES-treated patients (19,20), the results of the present
tudy cannot be generalized for the use of EES beyond the
pproved indications (off-label use). Third, the present study is
nderpowered to definitively examine low-frequency adverse
vents such as stent thrombosis, MI, and death. Finally,
omparative trials with emerging DES are required to deter-
ine the optimal platform for specific patient and lesion
ubtypes, particularly patients with diabetes.
onclusions
n this patient-level pooled analysis, EES compared with PES
esulted in significant and sustained reductions in TVF and
ACE at 3 years due to fewer MI and ischemic TLR events,
hich is consistent with superior safety and efficacy of the EES
latform.
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